Cocrystal Pharma, Inc.(COCP)Earnings, Financials & Key Ratios
COCP•NASDAQ
$1.39
$18M mkt cap·Price updated May 7, 2026
AboutCocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.Show more
- Revenue$0
- EBITDA-$18M+3.4%
- Net Income-$18M+2.7%
- EPS (Diluted)-1.72-90426.3%
- ROE-97.5%-78.8%
- ROIC-799.79%-32.3%
- Debt/Equity0.19+170.0%
COCP Key Insights
Cocrystal Pharma, Inc. (COCP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 1.5x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
COCP Price & Volume
Cocrystal Pharma, Inc. (COCP) stock price & volume — 10-year historical chart
Loading chart...
COCP Growth Metrics
Cocrystal Pharma, Inc. (COCP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM48.29%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM49.19%
Return on Capital
10 Years-52.18%
5 Years-51.72%
3 Years-70.87%
Last Year-91.62%
COCP Peer Comparison
Cocrystal Pharma, Inc. (COCP) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AGEN | 132.45M | 3.75 | -1102.94 | 10.37% | 0.1% | |||
 ABUS | 837.51M | 4.35 | -25.59 | 128.21% | -237.88% | -42.39% | 0.01 | |
 RDVT | 692.78M | 49.09 | 53.95 | 20.03% | 14.99% | 13.98% | 0.03 | |
 RLAY | 2.37B | 12.51 | -7.77 | 53.44% | -25.54% | -43.94% | 0.06 | |
 GILD | 166.4B | 134.06 | 19.77 | 2.4% | 30.99% | 42.33% | 1.09 | |
 ABBV | 358.42B | 202.64 | 85.50 | 8.57% | 6.91% | 62.15% | ||
 MRK | 277.34B | 112.29 | 15.42 | 1.18% | 28.12% | 36.14% | 0.96 | |
 REGN | 73.68B | 709.10 | 17.10 | 0.99% | 29.65% | 14.32% | 0.09 |
Compare COCP vs Peers
Cocrystal Pharma, Inc. (COCP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
COCP Income Statement
Cocrystal Pharma, Inc. (COCP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 6.56M | 2.01M | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | -100% | - | - | - | -69.32% | -100% | - | - | - | - |
| Cost of Goods Sold | 201K | 101K | 50K | 4M | 6.03M | 8.79M | 12.39M | 15.17M | 12.54M | 1.42M |
| COGS % of Revenue | - | - | - | 61% | 299.6% | - | - | - | - | - |
| Gross Profit | -201K▲ 0% | -101K▲ 49.8% | -50K▲ 50.5% | 2.56M▲ 5220.0% | -4.02M▼ 257.0% | -8.79M▼ 118.8% | -12.39M▼ 40.9% | -15.17M▼ 22.4% | -12.54M▲ 17.4% | -1.42M▲ 0% |
| Gross Margin % | - | - | - | 39% | -199.6% | - | - | - | - | - |
| Gross Profit Growth % | -76.32% | 49.75% | 50.5% | 5220% | -257.03% | -118.76% | -40.91% | -22.41% | 17.35% | - |
| Operating Expenses | 105.82M | 8.26M | 62.92M | 50.97M | 5.57M | 5.43M | 26.44M | 3.39M | 5.34M | 8.35M |
| OpEx % of Revenue | - | - | - | 776.45% | 276.37% | - | - | - | - | - |
| Selling, General & Admin | 4.14M | 2.44M | 4.35M | 4.86M | 5.57M | 5.43M | 5.75M | 5.99M | 5.34M | 4.25M |
| SG&A % of Revenue | - | - | - | 74.09% | 276.37% | - | - | - | - | - |
| Research & Development | 101.68M | 5.82M | 58.57M | 4M | 6.03M | 8.79M | 12.39M | 15.17M | 12.54M | 5.47M |
| R&D % of Revenue | - | - | - | 61% | 299.6% | - | - | - | - | - |
| Other Operating Expenses | -1K | -131K | 0 | 42.1M | -6.03M | -8.79M | 8.3M | -17.77M | -12.54M | -1.02M |
| Operating Income | -105.82M▲ 0% | -8.26M▲ 92.2% | -62.92M▼ 661.6% | -48.41M▲ 23.1% | -9.59M▲ 80.2% | -14.22M▼ 48.4% | -38.83M▼ 173.0% | -18.56M▲ 52.2% | -17.88M▲ 3.7% | -9.77M▲ 0% |
| Operating Margin % | - | - | - | -737.45% | -475.97% | - | - | - | - | - |
| Operating Income Growth % | -96.15% | 92.19% | -661.61% | 23.07% | 80.2% | -48.35% | -173.04% | 52.2% | 3.67% | - |
| EBITDA | -105.62M | -8.16M | -62.87M | -48.31M | -9.43M | -14.03M | -38.64M | -18.37M | -17.75M | -9.68M |
| EBITDA Margin % | - | - | - | -735.95% | -468.17% | - | - | - | - | - |
| EBITDA Growth % | -96.48% | 92.27% | -670.42% | 23.17% | 80.48% | -48.81% | -175.42% | 52.46% | 3.36% | 49.52% |
| D&A (Non-Cash Add-back) | 201K | 101K | 50K | 98K | 157K | 190K | 185K | 189K | 126K | 87K |
| EBIT | -105.82M | -7.49M | -62.57M | -2.3M | -9.59M | -14.22M | -18.14M | -21.16M | -17.88M | -9.76M |
| Net Interest Income | 0 | 0 | 0 | -19K | -8K | -4K | -2K | 640K | 537K | 142K |
| Interest Income | 126K | 0 | 0 | 0 | 0 | 4 | 2 | 640K | 537K | 142K |
| Interest Expense | 0 | 0 | 0 | 19K | 8K | 4K | 2K | 0 | 0 | 0 |
| Other Income/Expense | 1.55M | 769K | 294K | 237K | -62K | 36K | -8K | 575K | 374K | 97K |
| Pretax Income | -104.27M▲ 0% | -7.49M▲ 92.8% | -62.63M▼ 735.8% | -48.17M▲ 23.1% | -9.65M▲ 80.0% | -14.19M▼ 47.0% | -38.84M▼ 173.8% | -17.98M▲ 53.7% | -17.5M▲ 2.7% | -9.67M▲ 0% |
| Pretax Margin % | - | - | - | -733.84% | -479.05% | - | - | - | - | - |
| Income Tax | -29.39M | -6.88M | -13.58M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 28.19% | 91.82% | 21.69% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -74.87M▲ 0% | -613K▲ 99.2% | -49.05M▼ 7901.3% | -48.17M▲ 1.8% | -9.65M▲ 80.0% | -14.19M▼ 47.0% | -38.84M▼ 173.8% | -17.98M▲ 53.7% | -17.5M▲ 2.7% | -9.67M▲ 0% |
| Net Margin % | - | - | - | -733.84% | -479.05% | - | - | - | - | - |
| Net Income Growth % | -49.38% | 99.18% | -7901.31% | 1.79% | 79.97% | -47.03% | -173.79% | 53.69% | 2.67% | 48.29% |
| Net Income (Continuing) | -74.87M | -613K | -49.05M | -48.17M | -9.65M | -14.19M | -38.84M | -17.98M | -17.5M | -9.67M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -38.14▲ 0% | -0.30▲ 99.2% | -21.01▼ 6903.3% | -15.78▲ 24.9% | -2.01▲ 87.3% | -1.85▲ 8.0% | -4.77▼ 157.8% | -0.00▲ 100.0% | -1.72▼ 90426.3% | -0.88▲ 0% |
| EPS Growth % | -33.36% | 99.21% | -6903.33% | 24.89% | 87.26% | 7.96% | -157.84% | 99.96% | - | 49.19% |
| EPS (Basic) | -38.17 | -0.30 | -21.01 | -15.78 | -2.01 | -1.85 | -4.77 | -0.00 | -1.72 | - |
| Diluted Shares Outstanding | 1.96M | 2.01M | 2.33M | 3.05M | 4.8M | 7.69M | 8.14M | 9.65M | 10.17M | 10.99M |
| Basic Shares Outstanding | 1.96M | 2.01M | 2.33M | 3.05M | 4.8M | 7.69M | 8.14M | 9.65M | 10.17M | 10.99M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
COCP Balance Sheet
Cocrystal Pharma, Inc. (COCP) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 5.47M | 2.18M | 2.94M | 8.28M | 34.02M | 59.32M | 40.18M | 29.09M | 11.58M | 8.78M |
| Cash & Short-Term Investments | 3.64M | 748K | 2.72M | 7.42M | 33.01M | 58.7M | 37.14M | 26.35M | 9.86M | 7.73M |
| Cash Only | 3.64M | 748K | 2.72M | 7.42M | 33.01M | 58.7M | 37.14M | 26.35M | 9.86M | 7.73M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.31M | 1.29M | 0 | 644K | 556K | 0 | 716K | 890K | 1.22M | 0 |
| Days Sales Outstanding | - | - | - | 35.81 | 100.76 | - | - | - | - | - |
| Inventory | 0 | 29K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | 104.8 | - | - | - | - | - | - | - | - |
| Other Current Assets | 517K | 28K | 29K | 50K | 50K | 50K | 2.32M | 1.85M | 505K | 1.05M |
| Total Non-Current Assets | 119.41M | 119.25M | 65.62M | 20.25M | 20.23M | 20.07M | 662K | 2.17M | 1.88M | 1.66M |
| Property, Plant & Equipment | 280K | 119K | 384K | 1.11M | 1.09M | 931K | 616K | 2.12M | 1.85M | 1.57M |
| Fixed Asset Turnover | - | - | - | 5.92x | 1.85x | - | - | - | - | 0.00x |
| Goodwill | 65.19M | 65.19M | 65.19M | 19.09M | 19.09M | 19.09M | 0 | 0 | 0 | 0 |
| Intangible Assets | 53.91M | 53.91M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | -23.91M | 31K | -19.78M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 31K | -293K | 40K | 50K | 46K | 46K | 46K | 46K | 29K | 293K |
| Total Assets | 124.88M▲ 0% | 121.43M▼ 2.8% | 68.56M▼ 43.5% | 28.53M▼ 58.4% | 54.24M▲ 90.1% | 79.39M▲ 46.4% | 40.84M▼ 48.6% | 31.26M▼ 23.5% | 13.46M▼ 57.0% | 10.45M▲ 0% |
| Asset Turnover | - | - | - | 0.23x | 0.04x | - | - | - | - | 0.00x |
| Asset Growth % | -44.31% | -2.77% | -43.54% | -58.39% | 90.12% | 46.37% | -48.56% | -23.46% | -56.95% | -213.03% |
| Total Current Liabilities | 2.04M | 1.41M | 1.56M | 2.29M | 1.36M | 1.54M | 1.22M | 3.26M | 2.43M | 1.52M |
| Accounts Payable | 563K | 494K | 616K | 1.51M | 657K | 578K | 614K | 1.22M | 1.54M | 0 |
| Days Payables Outstanding | 1.02K | 1.79K | 4.5K | 137.74 | 39.74 | 23.99 | 18.09 | 29.4 | 44.89 | 205.73 |
| Short-Term Debt | 0 | 0 | 214K | 0 | 0 | 0 | 0 | 0 | 0 | 326K |
| Deferred Revenue (Current) | 0 | 0 | 464K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.48M | 569K | 127K | 7K | 187K | 116K | 130K | 1.69M | 0 | 1.19M |
| Current Ratio | 2.68x | 1.55x | 1.89x | 3.62x | 25.05x | 38.40x | 33.04x | 8.92x | 4.77x | 4.77x |
| Quick Ratio | 2.68x | 1.53x | 1.89x | 3.62x | 25.05x | 38.40x | 33.04x | 8.92x | 4.77x | 4.77x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 20.52M | 14.62M | 117K | 537K | 379K | 298K | 57K | 1.61M | 1.5M | 1.26M |
| Long-Term Debt | 0 | 1.01M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.26M |
| Capital Lease Obligations | 0 | 0 | 117K | 537K | 379K | 298K | 57K | 1.61M | 1.5M | 4.27M |
| Deferred Tax Liabilities | 20.46M | 13.58M | 19.78M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 63K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 22.56M | 16.03M | 1.67M | 2.82M | 1.74M | 1.84M | 1.27M | 4.88M | 3.93M | 2.78M |
| Total Debt | 0 | 1.01M | 331K | 817K | 596K | 534K | 297K | 1.85M | 1.81M | 1.58M |
| Net Debt | -3.64M | 259K | -2.39M | -6.6M | -32.41M | -58.17M | -36.85M | -24.5M | -8.05M | -6.15M |
| Debt / Equity | - | 0.01x | 0.00x | 0.03x | 0.01x | 0.01x | 0.01x | 0.07x | 0.19x | 0.19x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.16x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.63x |
| Interest Coverage | - | - | - | -2547.68x | -1198.25x | -3555.25x | -19414.50x | - | - | - |
| Total Equity | 102.32M▲ 0% | 105.4M▲ 3.0% | 66.89M▼ 36.5% | 25.71M▼ 61.6% | 52.51M▲ 104.2% | 77.55M▲ 47.7% | 39.57M▼ 49.0% | 26.38M▼ 33.3% | 9.52M▼ 63.9% | 7.67M▲ 0% |
| Equity Growth % | -38.95% | 3.01% | -36.54% | -61.57% | 104.24% | 47.7% | -48.98% | -33.32% | -63.91% | -240.53% |
| Book Value per Share | 52.12 | 52.42 | 28.66 | 8.42 | 10.95 | 10.09 | 4.86 | 2.73 | 0.94 | 0.70 |
| Total Shareholders' Equity | 102.32M | 105.4M | 66.89M | 25.71M | 52.51M | 77.55M | 39.57M | 26.38M | 9.52M | 7.67M |
| Common Stock | 714K | 24K | 30K | 36K | 71K | 8K | 8K | 10K | 10K | 13K |
| Retained Earnings | -137.43M | -138.04M | -187.09M | -235.26M | -244.91M | -259.09M | -297.93M | -315.91M | -333.42M | -339.82M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.35M | -1.36M | -983K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COCP Cash Flow Statement
Cocrystal Pharma, Inc. (COCP) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -14.65M | -6.9M | -8.29M | -1.56M | -9.83M | -12.72M | -21.43M | -14.67M | -16.48M | -16.48M |
| Operating CF Margin % | - | - | - | -23.81% | -488.08% | - | - | - | - | - |
| Operating CF Growth % | -42.05% | 52.9% | -20.09% | 81.15% | -528.92% | -29.39% | -68.53% | 31.58% | -12.4% | 151.24% |
| Net Income | -74.87M | -613K | -49.05M | -48.17M | -9.65M | -14.19M | -38.84M | -17.98M | -17.5M | -9.67M |
| Depreciation & Amortization | 201K | 101K | 50K | 98K | 157K | 190K | 388K | -1.39M | 126K | 160K |
| Stock-Based Compensation | 548K | 614K | 562K | 351K | 662K | 724K | 855K | 801K | 643K | 251K |
| Deferred Taxes | -29.41M | -6.88M | -13.58M | 45.85M | 54K | -49K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 90.97M | -807K | 53.61M | -133K | -177K | -195K | 18.87M | 1.56M | 110K | -358K |
| Working Capital Changes | -2.08M | 682K | 117K | 443K | -878K | 796K | -2.71M | 2.34M | 140K | -184.65K |
| Change in Receivables | 11K | 20K | 0 | -644K | 88K | 556K | -716K | 0 | -325K | 181.7K |
| Change in Inventory | 0 | 0 | 0 | -919K | 919K | -217K | 716K | 0 | 0 | 0 |
| Change in Payables | -2.02M | 281K | 0 | 919K | -919K | 217K | -321K | 2.05M | -895K | -854.79K |
| Cash from Investing | 3K | -40K | 1.37M | -145K | -240K | -52K | -74K | -118K | -8K | -12.56K |
| Capital Expenditures | -51K | -40K | -28K | -145K | -240K | -52K | -74K | -118K | -8K | -12.56K |
| CapEx % of Revenue | - | - | - | 2.21% | 11.92% | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 54K | 0 | 1.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 9.02K | 4.08M | 8.89M | 6.42M | 35.66M | 38.47M | -27K | 3.99M | 0 | 4.54M |
| Debt Issued (Net) | 0 | 1M | 981K | -214K | -121K | -39K | -27K | -7K | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 | 1000K | 0 | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 3K | 80K | 228K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | -5.64M▲ 0% | -2.86M▲ 49.2% | 1.98M▲ 169.0% | 4.72M▲ 138.8% | 25.59M▲ 442.7% | 25.7M▲ 0.4% | -21.54M▼ 183.8% | -10.79M▲ 49.9% | -16.49M▼ 52.8% | -5.29M▲ 0% |
| Free Cash Flow | -14.71M▲ 0% | -6.94M▲ 52.8% | -8.32M▼ 19.8% | -1.71M▲ 79.5% | -10.07M▼ 489.6% | -12.77M▼ 26.8% | -21.51M▼ 68.4% | -14.78M▲ 31.3% | -16.49M▼ 11.6% | -9.82M▲ 0% |
| FCF Margin % | - | - | - | -26.02% | -500% | - | - | - | - | - |
| FCF Growth % | -38.01% | 52.79% | -19.8% | 79.47% | -489.58% | -26.82% | -68.42% | 31.27% | -11.56% | 41.29% |
| FCF per Share | -7.49 | -3.45 | -3.56 | -0.56 | -2.10 | -1.66 | -2.64 | -1.53 | -1.62 | -1.62 |
| FCF Conversion (FCF/Net Income) | 0.20x | 11.26x | 0.17x | 0.03x | 1.02x | 0.90x | 0.55x | 0.82x | 0.94x | 1.01x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COCP Key Ratios
Cocrystal Pharma, Inc. (COCP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -55.48% | -0.59% | -56.94% | -104.04% | -24.67% | -21.81% | -66.32% | -54.54% | -97.5% | -126.11% |
| Return on Invested Capital (ROIC) | -61.76% | -6.07% | -55.47% | -86.85% | -36.68% | -54.05% | -263.57% | -604.66% | -799.79% | -799.79% |
| Gross Margin | - | - | - | 39% | -199.6% | - | - | - | - | - |
| Net Margin | - | - | - | -733.84% | -479.05% | - | - | - | - | - |
| Debt / Equity | - | 0.01x | 0.00x | 0.03x | 0.01x | 0.01x | 0.01x | 0.07x | 0.19x | 0.19x |
| Interest Coverage | - | - | - | -2547.68x | -1198.25x | -3555.25x | -19414.50x | - | - | - |
| FCF Conversion | 0.20x | 11.26x | 0.17x | 0.03x | 1.02x | 0.90x | 0.55x | 0.82x | 0.94x | 1.01x |
| Revenue Growth | -100% | - | - | - | -69.32% | -100% | - | - | - | - |
COCP Frequently Asked Questions
Cocrystal Pharma, Inc. (COCP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cocrystal Pharma, Inc. (COCP) grew revenue by 0.0% over the past year. Growth has been modest.
Cocrystal Pharma, Inc. (COCP) reported a net loss of $9.7M for fiscal year 2024.
Dividend & Returns
Cocrystal Pharma, Inc. (COCP) has a return on equity (ROE) of -97.5%. Negative ROE indicates the company is unprofitable.
Cocrystal Pharma, Inc. (COCP) had negative free cash flow of $9.8M in fiscal year 2024, likely due to heavy capital investments.
Explore More COCP
Cocrystal Pharma, Inc. (COCP) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates